European Journal of Pharmaceutical Sciences
Elsevier BV · NL · ISSN 09280987
动向摘要
Publication volume tightened while average citedness edged up.
Output shrank while citation impact rose. If you prioritise visibility per paper, this trend is relevant to your choice. Field-weighted citation impact moved from 1.89 to 1.91. Expect modestly higher average attention for articles here than in many places. RNA Interference and Gene Delivery rose from 2.0% to 5.4% of what the journal runs. Consider submitting RNA interference work when seeking topical fit. Gold open access accounts for 100.0%. Be prepared for article processing charges typical of full open access venues.
引用指标
基于 Scopus 与 OpenAlex 引用图谱。本站不提供 Clarivate 的 JCR 影响因子。
发文量与被引表现
发文量增长时被引表现是否同步。
主题变化
对比近 24 个月(2024-09 – 2026-08)与此前 24 个月(2022-09 – 2024-08)的占比。
- RNA Interference and Gene Delivery2.0%→5.4%+3.4%p此前近期
- Protein purification and stability2.4%→5.7%+3.3%p此前近期
- Lipid Membrane Structure and Behavior0.0%→3.2%+3.2%p此前近期
- Crystallization and Solubility Studies0.0%→2.1%+2.1%p此前近期
- Ocular Surface and Contact Lens0.0%→2.1%+2.1%p此前近期
- Drug Solubulity and Delivery Systems19.4%→15.7%−3.7%p此前近期
- Antibiotics Pharmacokinetics and Efficacy2.8%→0.0%−2.8%p此前近期
- Diabetes Treatment and Management2.8%→0.0%−2.8%p此前近期
- Pharmacological Effects and Toxicity Studies2.4%→0.0%−2.4%p此前近期
- Extracellular vesicles in disease2.4%→0.0%−2.4%p此前近期
近期高频术语
近期论文标题中相较以往显著增加的表述。
作者国家构成
将近 24 个月(2024-09 – 2026-08)与此前 24 个月(2022-09 – 2024-08)并列显示。
- CN41.3%→23.0%−18.3%p此前近期
- DE12.0%→21.1%+9.1%p此前近期
- US15.1%→15.4%+0.3%p此前近期
- FI7.2%→9.5%+2.3%p此前近期
- GB5.5%→9.1%+3.5%p此前近期
- HU0.0%→7.8%+7.8%p此前近期
机构发文 Top 5
2018 – 2026 期间在该期刊发表论文的前 5 家机构。
近期发表论文
20按发表日期最新的 20 篇,并非全部。
高被引论文
202018 – 2026 期间被引最高的 20 篇。
数据截至 2026-09-05